[Cis-radiation therapy of locally advanced bladder cancer].
Locally advanced bladder cancer (clinical stage T2-T4) of 11 patients and ureteral cancer (clinical stage T3) of 3 patients was treated concurrently by CDDP and irradiation. CDDP, total 200 mg, was administered 20 mg/day X5 day on the 1st week and 4th week combined with 2 GY/day irradiation, total doses 40 GY. CDDP was given on one or 2 hours after irradiation on the day. The results were significantly improved that the tumor could be controlled by TUR, and the pathological specimens showed marked tumor necrosis or degeneration. In 63.6% of 11 invasive bladder cancers, bladder function was preserved without any evidence of tumor recurrence or metastasis during 15-37 months. From these results, it is concluded that cis-radiation therapy may preserve the bladder with locally invasive cancer.
Itatani
H
H
Dept. of Urology, Sumitomo Hospital.
Utsunomiya
M
M
D000368:Aged; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D008875:Middle Aged; D014516:Ureteral Neoplasms / Q000188:drug therapy / Q000532:radiotherapy; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*
D002945:Cisplatin